{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C', 'antibody test are not required to also undergo Hepatitis C RNA testing.', '19']['2017N330177_04', 'CONFIDENTIAL', '205678', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'All assessments planned for participants in Study 205678 are shown in Table 1', '(Screening), Table 2 (On Study Assessments), and Table 3 (End of Treatment and Follow', 'Up Assessments).', 'Assessments for participants in the ocular sub-study are shown in Table 4. Participants', 'who are enrolled into the lyophilized configuration cohort of GSK2857916 (Figure 1)', 'will follow the same assessments and procedures as the main study.', 'The details of these assessments are provided in footnotes to the table, with more details', 'provided in Section 9.', '20']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 1', 'Schedule of Activities - Screening Assessments', 'Study Assessments\u00b9', 'Screen\u00b9', 'Notes', 'Informed Consent', '1.', 'All Screening assessments must be performed within 21 days prior to first dose unless otherwise specified. Informed Consent', 'Baseline Demographics', 'must be signed before any study-specific assessments are performed. Screening Assessment do not need to be repeated on Day', 'Medical History including', '1 of Cycle 1 (C1D1) unless otherwise specified.', 'disease history and', 'characteristics', '2.', 'All related SAEs are to be collected from consent through os follow-up', 'Physical Exam', '3.', 'Screening examination to be performed within 21 days prior to first dose. See Section 9.2.9 for the list of screening ophthalmic', 'Concomitant Medications', 'exam procedures.', 'Adverse Events 2', 'Safety', '4. Refer to Table 14 for a comprehensive list of clinical laboratory tests that must be collected for all participants. If labs are', 'Ocular Exam\u00b3', 'completed within 72 hours prior to the first dose, this assessment need not be repeated on C1D1', 'ECOG Performance Status', '5. Albumin/Creatinine ratios (spot urine from first void) at screening, C1, and every other cycle thereafter (C3, C5, C7) (local labs or', 'Vital Signs (BP, HR, Body', 'central if local not available)', 'Temperature)', 'Weight and Height', '6. Hepatitis: If the participant is hepatitis C virus (HCV) positive by serology, an additional Hep C RNA testing may be done to', 'Hematology4', 'determine participant eligibility (if Hep C RNA is negative, participant is eligible).', 'Clinical chemistry4', '7.', 'Troponin I will be measured at the local lab, or by central laboratory if not available locally. If cardiac workup is required due to', 'Urine Dipstick4', 'safety concerns during the study, troponin I should be measured as clinically indicated.', 'eGFR (by MDRD formula- see', 'X', '8.', 'Appendix 10)', 'B-type natriuretic peptide (BNP) to be measured locally, or by a central laboratory if not available locally, at screening; if cardiac', 'Spot Urine (albumin/creatinine', 'workup is required due to safety concerns during the study, BNP should be measured as clinically indicated.', 'ratio)4 5', '9.', 'Perform only in women of child-bearing potential. A serum pregnancy test must be performed', 'CRP', 'at screening, and subsequent pregnancy tests may be either serum or urine. If test is completed within 72 hours prior to the first', 'HBsAg, HBcAb, and hepatitis C', 'dose, this assessment need not be repeated on Day 1 of Cycle 1. For questionable cases of whether a participant is of non-child', 'Ab. 6', 'bearing potential, obtain follicle stimulating hormone (FSH) and estradiol. See Section 6.1, Section 9.2.8, and Appendix 5 for', 'more details.', 'Troponin 17', '10. Echocardiography for LVEF performed within 35 days prior to first dose is acceptable as screening value.', 'BNP8', 'X', '11. Skeletal Survey: Imaging of bones for lytic lesions by a method aligned with the institutional guidance (ex: X-ray, CT, or MRI).', 'Skeletal survey results within 30 days prior to C1D1 are acceptable. For sites in Germany: Only MRI is allowed to be used as', 'Pregnancy Test 9', 'X', 'imaging modality for participants.', 'ECHO10', 'X', '12. Imaging is only required for participants with extramedullary disease (CT, MRI, or PET/CT can be applied per local guidance).', '12-lead ECG', 'Screening assessment may be performed up to 30 days prior to C1D1. The same modality should be used throughout the study', '21']\n\n###\n\n", "completion": "END"}